Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

Larry E Miller¹
Angela K Zimmermann¹
William G Herbert¹,²

¹Miller Scientific Consulting, Inc., Asheville, NC, ²Department of Human Nutrition, Foods, and Exercise, Virginia Tech, Blacksburg, VA, USA

Introduction
Spinal cord injury (SCI) is a traumatic event with a global incidence of 23 cases per million, representing 180,000 cases per annum worldwide.¹ Despite concerted efforts to develop medical and surgical interventions intended to minimize chronic neurological deficit with acute SCI, recovery of physical function following SCI remains limited due to rapid degenerative processes such as neurotoxicity, vascular dysfunction, glial
sccarring, neuroinflammation, apoptosis, and demyelination. Consequently, spinal cord-injured patients have increased risks of osteoporosis, cardiovascular disease, respiratory problems, pressure ulcers, and muscular spasticity and contractures compared to the general population.3,4

Recovery of locomotion is a main priority for spinal cord-injured patients.5 In addition to overcoming the obvious mobility and social issues related to the inability to stand or walk, regular ambulation may profoundly combat secondary medical problems associated with lack of weight-bearing activity in SCI patients.6 Orthotic technologies such as hip-knee-ankle-foot orthosis (HKAFO) and reciprocating gait orthosis (RGO) have been employed with mixed success as a means of addressing this critical unmet health care need in the SCI population. The main limitation of these devices is a high metabolic demand such that most patients eventually discontinue their use.7-10 Since the health benefits of physical activity are largely dependent on exercise frequency and duration,11 these traditional orthotic technologies likely have limited utility in ameliorating the chronic effects of inactivity due to SCI.

Powered exoskeletons are prescription devices comprising an external, powered, motorized orthosis that is placed over a person’s paralyzed or weakened limbs for the purpose of facilitating standing, walking, climbing stairs, and performing activities of daily living. Powered exoskeletons are classified as class II medical devices by the US Food and Drug Administration.12 Although several systematic reviews of powered exoskeletons have recently been published,13-15 there are no known meta-analyses that have examined the clinical effectiveness and safety of powered exoskeletons in spinal cord-injured patients. We report herein the first meta-analysis of powered exoskeletons in SCI patients and conclude that exoskeleton use allows safe ambulation in real-world settings at a physical activity intensity conducive to prolonged use and known to yield health benefits.

Methods
Eligibility criteria and information sources
This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).16 We searched MEDLINE and EMBASE for randomized or nonrandomized controlled studies and prospective or retrospective case series with no date restrictions on the safety and effectiveness of powered exoskeleton-assisted walking in adult patients with SCI. The details of the MEDLINE search strategy are listed in Table 1. Additionally, manual searches were conducted using the Directory of Open Access Journals, Google Scholar, and the reference lists of included papers and other relevant meta-analyses. The final search was conducted on November 30, 2015.

Study selection
One reviewer selected studies for inclusion in the review. Identified articles were independently assessed by a second reviewer to confirm eligibility. Disagreements were resolved by discussion and consensus. Titles and abstracts were initially screened to exclude all manuscripts published in non-English journals. Next, review articles, commentaries, letters, animal or in vitro studies, studies with less than three patients to eliminate bias inherent with case reports, and obviously irrelevant articles were excluded. Full texts of the remaining manuscripts were retrieved and reviewed. Studies were excluded if mixed diagnoses were included and SCI-specific data were not reported; training was limited to a treadmill; or the protocol utilized upper body exoskeletons, single- or dual-joint exoskeletons, hybrid exoskeletons that required volitional contraction of the lower extremities, or exoskeletons that required use of a walker.

Data extraction
A database was developed, pilot-tested, and subsequently refined to develop the final data extraction database. One
reviewer extracted the data from included studies and a second reviewer checked the extracted data for accuracy. Disagreements were resolved by discussion and consensus.

Outcomes
Main outcomes were categorized by ambulatory performance, physiological demand, health benefits, and safety. Ambulatory performance outcomes included assessment of ability to ambulate without physical assistance by the end of the training program and distance walked during a 6-minute walk test. Ability to walk without physical assistance was defined as ambulation using crutches or walker, but with no physical contact by a therapist for weight shift or balance support. The 6-minute walk test measures the distance walked over a 6-minute period and serves as an indicator of submaximal aerobic capacity.\(^1\) Indicators of physiological demand of exoskeleton walking included metabolic equivalents (METs), rating of perceived exertion (RPE), and physiological cost index. The MET concept is useful for expressing the energy cost of physical activities. One MET represents the amount of oxygen consumed during seated rest. In paraplegics, 1 MET is equivalent to 2.7 mL O\(_2\)/kg.\(^2\) Each unit increase in METs represents a multiple of the energy used by the body at rest. For reference, exertion with physical activity can be classified as light (<3 METs), moderate (3–6 METs), or vigorous (>6 METs). Rating of perceived exertion values was self-reported according to the Borg 6–20 scale.\(^3\) For reference, a value of 6 represents no exertion, 9–11 represents very light to light exertion, 13–15 represents somewhat hard to hard exertion, 17 represents very hard, and 20 represents maximal exertion. Physiological cost index serves as an indicator of ambulation efficiency and was calculated as heart rate during exoskeleton-assisted ambulation minus resting heart rate divided by walking velocity.\(^4\) Health benefit outcomes included self-reported decreases in spasticity and improvements in bowel movement regularity with exoskeleton use. Safety parameters included serious adverse events, falls, and bone fractures reported at any time during the study, regardless of cause.

Data analysis
For each main outcome, fixed and random effects meta-analysis models were developed; data from the random effects model were preferentially reported in the manuscript based on the a priori assumption that treatment effects would be heterogeneous, given the differences in exoskeletons and patient characteristics among studies. For each main outcome, the pooled estimate and 95% confidence interval (CI) were calculated. A forest plot was used to illustrate the individual study findings and the pooled meta-analysis results. We used the \(F\) statistic to estimate heterogeneity of effects across studies with values of ≤25%, 50%, and ≥75% representing low, moderate, and high inconsistency, respectively.\(^5\) Statistical analyses were performed using MedCalc version 12.5 (MedCalc Software, Ostend, Belgium) and Comprehensive Meta-Analysis version 2.2 (Biostat, Englewood, NJ, USA).

Results
Study selection
Our initial database search retrieved 105 titles and abstracts; handsearching relevant bibliographies identified three additional records. After screening records for inclusion criteria, 48 full-text articles were reviewed for eligibility. Ultimately, 14 studies\(^6\)-\(^8\) representing 111 distinct patients were included in the final analysis. A flow diagram of study identification and selection is shown in Figure 1.

Study characteristics
All studies included in this review were prospective and conducted at single centers in the US (eleven), the UK (one), Iran (one), and Israel (one). Sample sizes ranged from 3 to 16 patients (median 7).

Patient characteristics
Mean patient age was 37 years, with males accounting for 83% of the patients. The level of injury varied considerably among studies, with most injuries located between T1 and T12. Nearly three in four patients presented with complete SCI (Table 2).

Powered exoskeleton training protocols
The ReWalk™ (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies,\(^9\)-\(^12\),\(^22\)-\(^25\),\(^27\)-\(^33\),\(^35\) Ekso® (Ekso Bionics, Richmond, CA, US) in three studies,\(^29\)-\(^31\) Indego™ (Parker Hannifin Corp., Cleveland, OH, US) in two studies,\(^26\),\(^28\) and an unspecified exoskeleton in one study.\(^33\) Representative images and complete specifications of the ReWalk, Ekso, and Indego powered exoskeletons are available elsewhere.\(^36\)-\(^38\) The study of Arazpour et al\(^33\) was a randomized cross-over trial comparing exoskeleton, RGO, and HKAFO; the remaining studies were prospective case series. There was considerable variation in training programs among studies, for a duration ranging from 1 to 24 weeks. Typically, programs were conducted three times per week for 60–120 minutes per session. Ten studies\(^22\),\(^23\),\(^25\)-\(^27\),\(^29\),\(^31\),\(^33\)-\(^35\) utilized training programs exclusively.
on flat indoor surfaces, while four studies\textsuperscript{24,28,30,32} incorporated more complex forms of training, including walking outdoors, navigating obstacles, climbing stairs, and performing activities of daily living (Table 3).

### Ambulatory performance

Following the exoskeleton training program, 76\% (95\% CI: 59\%–90\%) of patients were able to ambulate with no physical assistance (Figure 2). Significant heterogeneity among studies was noted for this outcome ($I^2 = 73\%$, $P < 0.001$). In the randomized controlled trial of Arazpour et al.\textsuperscript{22} 6-minute walk test velocity and distance were superior with powered exoskeleton vs RGO and HKAFO (Figure 3). Across all powered exoskeleton studies, the weighted mean distance covered during a 6-minute walk test was 98 m (95\% CI: 80–117 m) (Figure 4). Significant heterogeneity among studies was also noted for this outcome ($I^2 = 85\%$, $P < 0.001$).

### Physiological demand

In the randomized controlled trial of Arazpour et al.\textsuperscript{22} the physiological cost index was $\sim 50\%$ lower with powered exoskeleton vs RGO and HKAFO (Figure 3). Across all powered

---

### Table 2 Baseline patient characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Male (n)</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>BMI (kg/m(^2))</th>
<th>LOI(^a)</th>
<th>AIS</th>
<th>Time post-injury (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arazpour et al\textsuperscript{21}</td>
<td>5</td>
<td>3</td>
<td>27</td>
<td>167</td>
<td>58</td>
<td>21</td>
<td>T6-T12</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Asselin et al\textsuperscript{22}</td>
<td>8</td>
<td>7</td>
<td>46</td>
<td>–</td>
<td>78</td>
<td>–</td>
<td>T1-T11</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Benson et al\textsuperscript{27}</td>
<td>10</td>
<td>10</td>
<td>32</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>C7-L1</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Esquenazi et al\textsuperscript{24}</td>
<td>12</td>
<td>8</td>
<td>38</td>
<td>177</td>
<td>74</td>
<td>23</td>
<td>T3-T12</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Evans et al\textsuperscript{25}</td>
<td>5</td>
<td>4</td>
<td>42</td>
<td>180</td>
<td>70</td>
<td>21</td>
<td>T6-T12</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Fineberg et al\textsuperscript{26}</td>
<td>6</td>
<td>5</td>
<td>45</td>
<td>174</td>
<td>71</td>
<td>23</td>
<td>T1-T11</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Hartigan et al\textsuperscript{27}</td>
<td>16</td>
<td>13</td>
<td>36</td>
<td>177</td>
<td>75</td>
<td>24</td>
<td>C5-L1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Kolakowsky-Hayner et al\textsuperscript{28}</td>
<td>7</td>
<td>5</td>
<td>30</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>T4-T11</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Kozlowski et al\textsuperscript{29}</td>
<td>7</td>
<td>7</td>
<td>36</td>
<td>178</td>
<td>82</td>
<td>24</td>
<td>C4-L1</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Kressler et al\textsuperscript{30}</td>
<td>3</td>
<td>2</td>
<td>30</td>
<td>177</td>
<td>75</td>
<td>24</td>
<td>T1-T9</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Spungen et al\textsuperscript{31}</td>
<td>7</td>
<td>6</td>
<td>44</td>
<td>175</td>
<td>73</td>
<td>24</td>
<td>T1-T11</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Talaty et al\textsuperscript{32}</td>
<td>12</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>C7-T12</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Yang et al\textsuperscript{33}</td>
<td>12</td>
<td>10</td>
<td>46</td>
<td>173</td>
<td>75</td>
<td>25</td>
<td>C8-T11</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>Zeilig et al\textsuperscript{34}</td>
<td>6</td>
<td>6</td>
<td>33</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>T5-T12</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Notes:** \(^a\)Represents the cephalad to caudal range. Dash indicates unspecified.

**Abbreviations:** AIS, American Spinal Injury Association Impairment Scale; BMI, body mass index; LOI, level of injury.
### Table 3 Powered exoskeleton training protocols

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Exoskeleton</th>
<th>Training environment</th>
<th>Obstacles</th>
<th>Stairs</th>
<th>ADLs</th>
<th>Training volume</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Indoor walking</td>
<td>Outdoor walking</td>
<td>Obstacles</td>
<td>Stairs</td>
<td>ADLs</td>
</tr>
<tr>
<td>Arazpour et al&lt;sup&gt;21&lt;/sup&gt;</td>
<td>RCT</td>
<td>–</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asselin et al&lt;sup&gt;22&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benson et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Esquenazi et al&lt;sup&gt;24&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evans et al&lt;sup&gt;25&lt;/sup&gt;</td>
<td>PCS</td>
<td>Indego</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fineberg et al&lt;sup&gt;26&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hartigan et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>PCS</td>
<td>Indego</td>
<td>X</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Kolakowsky-Hayner et al&lt;sup&gt;28&lt;/sup&gt;</td>
<td>PCS</td>
<td>Ekso</td>
<td>X&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kozlowski et al&lt;sup&gt;29&lt;/sup&gt;</td>
<td>PCS</td>
<td>Ekso</td>
<td>X</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kressler et al&lt;sup&gt;30&lt;/sup&gt;</td>
<td>PCS</td>
<td>Ekso</td>
<td>X&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spungen et al&lt;sup&gt;31&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td>X</td>
<td>X&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X&lt;sup&gt;j&lt;/sup&gt;</td>
<td>X&lt;sup&gt;k&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Talaty et al&lt;sup&gt;32&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zeilig et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>PCS</td>
<td>ReWalk</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Brackets represent an estimate. Dash indicates unspecified, blank spaces indicate not utilized. 
<sup>a</sup>Includes walking up and down stairs; 
<sup>b</sup>Includes visiting a café, upright cooking, shopping;
<sup>c</sup>Includes concrete walkway, city sidewalks, and grass;
<sup>d</sup>Includes ramps with slope ≤5°;
<sup>e</sup>Includes entering an elevator, riding to another floor, and exit without requiring the elevator door to be held open;
<sup>f</sup>Includes tethered indoor walking;
<sup>g</sup>Includes walking on carpet, rough concrete surfaces, and ramps with slope ≤8°;
<sup>h</sup>Includes opening doors, pushing button to summon, enter, and exit elevators, and standing at counter and retrieve an item from high cupboard;
<sup>i</sup>Includes walking on concrete and uneven ground surfaces;
<sup>j</sup>Includes walking on carpet, up and down a slight slope, and up and down a curb;
<sup>k</sup>Includes navigating a push button electric door, an elevator, and a revolving door.

**Abbreviations:** ADLs, activities of daily living; PCS, prospective case series; RCT, randomized controlled trial; min, minutes.

Exoskeleton studies, the metabolic demand of exoskeleton-assisted walking was 3.3 METs (95% CI: 2.2–4.4 METs) (Figure 5). For reference, 3.3 METs is equivalent to the self-reported exertion of an able-bodied individual walking at 3 miles per hour. Significant heterogeneity was identified among studies ($I^2=98\%$, $P<0.001$). Rating of perceived exertion during powered exoskeleton walking was 10 (95% CI: 9–11) and results were consistent among studies ($I^2=0\%$, $P=0.33$).

![Figure 2](https://www.dovepress.com/)

**Figure 2** Ability to ambulate using a powered exoskeleton without physical assistance.

**Notes:** Data represent the proportion of subjects who were able to ambulate using an exoskeleton without physical assistance at the end of the training period. Fixed effects estimates: 76.2% (95% CI: 66.7%–84.1%); random effects estimates: 76.2% (95% CI: 58.6%–90.1%); $I^2=73\%$, $P<0.001$.

**Abbreviation:** CI, confidence interval.
Health benefits

Health benefits related to exoskeleton-assisted ambulation were inconsistently reported. In five studies, 38% (95% CI: 19%–59%) of patients reported decreases in spasticity with exoskeleton training; heterogeneity among studies was moderate ($I^2=46\%, P=0.12$) (Figure 7). In three studies, 61% (95% CI: 20%–95%) of patients reported improvements in bowel movement regularity with exoskeleton training (Figure 8). Significant heterogeneity was identified among studies ($F=81\%, P<0.01$).

Safety

No serious adverse events were reported in any included study. The incidence of a fall at any time during the training program was 4.4% (95% CI: 1.0%–10.0%) (Figure 9). All three reported falls occurred in a single study while tethered and none resulted in injury. Falls were due to programming errors using a first-generation Ekso exoskeleton in two participants and due to malfunctioning of specialized forearm

---

**Figure 3** Outcomes of randomized controlled trial comparing powered exoskeleton, reciprocating gait orthosis, and hip-knee-ankle-foot orthosis.

**Notes:** A is PCI, B is 6-min walk distance, and C is walking velocity. *Exoskeleton outcomes superior to RGO and HKAFO for walking velocity (both $P<0.001$), 6-minute walk distance ($P=0.03$ vs RGO; $P=0.01$ vs HKAFO), and PCI (both $P<0.001$).

**Abbreviations:** HKAFO, hip-knee-ankle-foot orthosis; PCI, physiological cost index; RGO, reciprocating gait orthosis.

---

**Figure 4** Six-minute walk test results with a powered exoskeleton.

**Notes:** Data represent the number of meters walked with exoskeleton at the end of the training period. Fixed effects estimates: 99 m (95% CI: 92–106 m); random effects estimates: 98 m (95% CI: 80–117 m); $F=85\%, P<0.001$.

**Abbreviation:** CI, confidence interval.
Figure 5 Metabolic equivalents with powered exoskeleton walking.
Notes: Data represent the number of metabolic equivalents (METs) required for exoskeleton walking at the end of the training period. METs were calculated as 1 MET per 2.7 mL O₂/kg based on the estimated or measured maximal aerobic capacity values, unless otherwise specified. Fixed effects estimates: 3.9 METs (95% CI: 3.8, 4.0 METs); random effects estimates: 3.3 METs (95% CI: 2.2, 4.4 METs); I²=98%, P<0.001.
Abbreviation: CI, confidence interval.

Figure 6 Rating of perceived exertion with powered exoskeleton walking.
Notes: Data represent subjective rating of perceived exertion (RPE; Borg 6–20 scale) required for exoskeleton walking at the end of the training period. Fixed and random effects estimates: 10.1 (95% CI: 9.0, 11.3); I²=0%, P=0.97.
Abbreviations: CI, confidence interval; RPE, rating of perceived exertion.
**Figure 7** Spasticity decreases with powered exoskeleton training.

**Notes:** Data represent the proportion of subjects who reported decreases in spasticity with exoskeleton training. Fixed effects estimates: 36.7% (95% CI: 21.9%, 53.6%); random effects estimates: 37.7% (95% CI: 18.5%, 59.2%); I²=46%, P=0.12.

**Abbreviation:** CI, confidence interval.

**Figure 8** Improvements in bowel movement regularity with powered exoskeleton training.

**Notes:** Data represent the proportion of subjects who reported improvements in bowel movement regularity with exoskeleton training. Fixed effects estimates: 57.7% (95% CI: 37.3%, 76.3%); random effects estimates: 60.9% (95% CI: 19.3%, 94.5%); I²=81%, P<0.01.

**Abbreviation:** CI, confidence interval.
crutches that had been discontinued in one participant. The incidence of bone fracture at any time during the training program was 3.4% (95% CI: 0.7%–8.1%) (Figure 10). The single reported event was a hairline talus fracture that required no treatment in a patient who did not undergo bone density screening.24

**Discussion**

This is the first known meta-analysis of the clinical effectiveness and safety of powered exoskeletons in SCI patients. The results of this study show that use of a powered exoskeleton allows safe ambulation in real-world settings at a physical activity intensity conducive to prolonged use and known to yield health benefits.

Most patients included in this review presented with complete SCI. Generally, less than 5% of such patients have the ability to ambulate without physical assistance. Following an exoskeleton training program, 67% of patients in this review were able to engage in exoskeleton-assisted ambulation without physical assistance. Since training programs were limited to only five or six sessions in some studies,26,28,29 it is plausible that the ability to ambulate without physical assistance may be somewhat higher with training programs of adequate duration that emphasize identification of safe environments for exoskeleton use, use of safety features, and operation in environments representative of actual use.

For studies that reported 6-minute walk test results after exoskeleton training, the gait speed achieved suggested encouraging potential for independent ambulation in home and community environments. Physiologic demands during powered exoskeleton ambulation averaged 3.3 METs for the included studies, which represents 24%–35% of peak oxygen uptake during exercise in SCI patients.23 These data suggest that exoskeleton use allows SCI patients to engage in physical activity at an intensity that conveys health benefits, yet does not result in early fatigue, as with older orthotic technologies such as HKAFO and RGO. Powered exoskeleton walking perceived exertion corresponded to fairly light to light exertion, implying that patients felt they could sustain ambulation for extended durations. This assertion is supported by the fact that several studies in this review utilized exoskeleton-assisted training programs up to 2 hours duration per session. In contrast, spinal cord-injured adults can ambulate only 20–50 m at a time with an RGO before stopping due to fatigue.10 The randomized controlled trial of Arazpour et al22
confirmed that SCI patients can walk faster and with less effort using a powered exoskeleton vs RGO and HKAFO. Physical activity at 3.3 METs maintained for only 1 hour per day, 3 days per week, corresponding to 10 MET hours per week, is associated with preventive health benefits including cardiovascular and all-cause mortality risk reduction of 20% in the general adult population. For SCI patients, those same health benefits should be a reasonable expectation. In addition, several other benefits may accrue to SCI patients as a result of intermittent standing and habitual ambulating activity with the powered exoskeleton, including increasing upper body muscular fitness, minimizing declines in bone mineral density by periodic exposure to gravitational and muscular loading forces, improved circulatory response, and countering the independent health risks associated with prolonged sitting. Indeed, clinically relevant improvements were found in self-reports for muscle spasticity and bowel movement regularity following exoskeleton training. A potential focus for future research would be to assess the long-term health and cost benefits associated with chronic powered exoskeleton use. Assuming regular exoskeleton use sufficient to yield the aforementioned health benefits, it is likely that the initial expense of providing personal exoskeletons for home use to individuals with SCI (typically $70,000–$100,000) may be offset by savings attributable to prevention of physical maladies and associated costs in SCI patients, which may ultimately result in overall savings to the health care system.

The safety of exoskeleton-assisted ambulation was demonstrated by no reports of serious adverse events and a low incidence of tethered falls and fractures that were subsequently addressed by refinements to exoskeleton design and patient selection criteria. Falls were identified in a single study that used an early prototype exoskeleton; injuries to subjects were prevented by a tethering device. The instance of a hairline talus fracture occurring in a subject who did not undergo bone density screening suggests that osteoporosis/osteopenia should be viewed as a relative contraindication for SCI patients being considered for exoskeleton ambulatory training. Although there are subtle differences when comparing features of available exoskeleton, generally accepted criteria for safe use include ability to stand using an assistive device and absence of severe neurological injury, severe spasticity, significant contractures, osteoporosis, and existing fractures. On balance, falls and fractures are known risks for all assisted walking devices for SCI patients such as KAFO and RGO, which mandate similar patient screening measures.
Four of the 14 studies included more complex forms of ambulatory training relevant to daily living. Examples of these activities included walking on uneven or carpeted surfaces and grades, negotiating curbs outdoors, climbing stairs, entering/exiting of elevators, and ordering at a café. It is important to note that in the studies that utilized complex training, no serious adverse events, falls, or fractures were reported. While these activities were performed under the supervision of trained clinicians, the outcomes indicate that a powered exoskeleton uniquely facilitates independent performance of tasks relevant to the home and community settings.

Limitations
As with any meta-analysis, interpretation of outcomes may be confounded by issues related to individual study designs and by issues inherent in the analysis of summary data. There was considerable variation in the consistency of outcome reporting among studies. Development of minimum reporting standards for powered exoskeleton clinical trials is recommended to facilitate comparisons among studies. Additionally, the number of studies limited our ability to explore sources of heterogeneity such as age, level of injury, and duration of injury. Despite these limitations, this report represents the most comprehensive synthesis of data for powered exoskeleton-assisted walking in patients with SCI.

Conclusion
In conclusion, powered exoskeletons allow patients with SCI to safely ambulate in real-world settings at a physical activity intensity conducive to prolonged use and known to yield health benefits.

Disclosure
This research was supported by ReWalk Robotics, Inc. (Marlborough, MA, USA). The authors report no conflicts of interest in this work.

References


